Benzinga

Benzinga

Benzinga

jeudi, août 20

Bristol-Myers Squibb Co

BMYNYSE
Trade with Public
Trade with Public
$65.47
-2.14-3.17%
À la clôture: Aug 20, 5:00 PM EST
$65.63
0.160.24%
Après les heures: 6:10 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatDividendesComparerOptionsRapport sur les stocks

Bristol-Myers Squibb Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bristol-Myers Squibb (BMY).

Price Target Range — 13 Quarters

Analyst Consensus — 24 Analysts

10Buy
13Hold
1Sell
Consensus RatingNeutral# Analysts24Avg. Consensus PT$62Upside to Avg. PT-5.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 5, 2026Argus ResearchJasper HellwegUpgradeHold→Buy$75
Aug 3, 2026CitigroupGeoff MeachamPT RaiseNeutral$66→$70
More with Benzinga EdgeGet Access

Analyst Ratings News

Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma Treatment

Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therapy approval.
Vandana Singh

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst ratings for high-yield stocks in health care.
Avi Kapoor

PRO
Argus Research Upgrades Bristol-Myers Squibb to Buy, Announces $75 Price Target

Argus Research analyst Jasper Hellweg upgrades Bristol-Myers Squibb (NYSE:BMY) from Hold to Buy and announces $75 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $70

Citigroup analyst Geoff Meacham maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and raises the price target from $66 to $70.
Benzinga Newsdesk

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.
Vandana Singh

PRO
RBC Capital Maintains Sector Perform on Bristol-Myers Squibb, Raises Price Target to $64

RBC Capital analyst Trung Huynh maintains Bristol-Myers Squibb (NYSE:BMY) with a Sector Perform and raises the price target from $60 to $64.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved